Healthcare - Biotechnology - NASDAQ - US
$ 22.92
-14.7 %
$ 1.62 B
Market Cap
-7.99
P/E
BALANCE SHEET
356 M
ASSETS
155 M
LIABILITIES
200 M
EQUITY
BALANCE SHEET DECOMPOSITION
Balance Sheet Decomposition
Nurix Therapeutics, Inc.
| Current Assets | 296 M |
| Cash & Short-Term Investments | 288 M |
| Receivables | 0 |
| Other Current Assets | 7.6 M |
| Non-Current Assets | 60.1 M |
| Long-Term Investments | 7.42 M |
| PP&E | 48 M |
| Other Non-Current Assets | 4.72 M |
| Current Liabilities | 87 M |
| Accounts Payable | 6.4 M |
| Short-Term Debt | 15 M |
| Other Current Liabilities | 65.6 M |
| Non-Current Liabilities | 68.1 M |
| Long-Term Debt | 23.1 M |
| Other Non-Current Liabilities | 45 M |
Balance Sheet
Millions
| Nov-2023 | Nov-2022 | Nov-2021 | Nov-2020 | Nov-2019 | Nov-2018 | |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Cash & Cash Equivalents | 54.6 | 64.5 | 80.5 | 119.4 | 34.8 | 25.6 |
| Short Term Investments | 233.3 | 244.7 | 215.2 | 161.8 | 2.9 | 13.4 |
| Receivables | 0 | 0 | 6.2 | 11.3 | 0 | 0 |
| Inventory | 0 | (1.1) | 1 | 0 | 0 | 0 |
| Other Current Assets | 7.6 | 9.3 | 9.4 | 5.9 | 1.6 | 1.6 |
| Total Current Assets | 295.5 | 318.4 | 311.1 | 298.4 | 39.4 | 40.7 |
| PP&E | 48.0 | 29.5 | 25.3 | 6.7 | 3.9 | 4.4 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Long Term Investments | 7.4 | 63.9 | 137.2 | 90.9 | 0.5 | 0.2 |
| Other Long Term Assets | 4.7 | 4.9 | 3.1 | 0.3 | 0.3 | 0.2 |
| Other Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 355.6 | 416.8 | 476.8 | 396.3 | 44.0 | 45.4 |
| LIABILITIES | ||||||
| Accounts Payable | 6.4 | 5.1 | 6.7 | 3.4 | 1.6 | 1.3 |
| Short Term Debt | 15.0 | 11.1 | 7.7 | 0 | 0 | 0 |
| Other Current Liabilities | 17.5 | 16.8 | 10.6 | 8.3 | 4.9 | 3.1 |
| Total Current Liabilities | 87.0 | 70.7 | 66.3 | 44.5 | 16.1 | 32.8 |
| Long Term Debt | 23.1 | 6.4 | 9.2 | 0 | 0 | 0 |
| Deferred Tax Income | 0 | 3.3 | 3.3 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 | 0.8 | 49.9 | 49.4 |
| Total Liabilities | 155.1 | 113.1 | 134.5 | 106.1 | 101.8 | 82.2 |
| EQUITY | ||||||
| Common Stock | 49 K | 47 K | 45 K | 39 K | 4 K | 3 K |
| Retained Earnings | (545.2) | (401.3) | (220.9) | (103.7) | (60.5) | (38.8) |
| Other Accumulative Comprehensive Income/Loss | (0.7) | (4.3) | (0.6) | 87 K | 2 K | 4 K |
| Total Equity | 200.5 | 303.7 | 342.3 | 290.3 | (57.7) | (36.8) |
| Total Liabilities and Equity | 355.6 | 416.8 | 476.8 | 396.3 | 44.0 | 45.4 |
| SHARES OUTSTANDING | ||||||
| Common Shares Outstanding | 54.3 | 48.6 | 42.9 | 15.7 | 38.8 | 16.1 |